The stock of Iovance Biotherapeutics Inc (NASDAQ:IOVA) last traded at $14.93, up 7.41% from the previous session.
IOVA stock price is now 29.91% away from the 50-day moving average and 97.82% away from the 200-day moving average. The market capitalization of the company currently stands at $4.17B.
With the price target of $12, Goldman recently initiated with Buy rating for Iovance Biotherapeutics Inc (NASDAQ: IOVA). On September 18, 2023, Barclays reiterated its ‘Overweight’ rating on the stock by increasing its target price from $40 to quote $18, while ‘Wells Fargo’ rates the stock as ‘Overweight’
In other news, Rothbaum Wayne P., Director bought 5,000,000 shares of the company’s stock on Feb 20 ’24. The stock was bought for $45,750,000 at an average price of $9.15. Upon completion of the transaction, the Director now directly owns 28,067,333 shares in the company, valued at $419.05 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 20 ’24, Director MCPEAK MERRILL A bought 250,000 shares of the business’s stock. A total of $2,287,500 was incurred on buying the stock at an average price of $9.15. This leaves the insider owning 320,150 shares of the company worth $4.78 million. A total of 21.24% of the company’s stock is owned by insiders.
During the past 12 months, Iovance Biotherapeutics Inc has had a low of $3.21 and a high of $18.33. As of last week, the company has a debt-to-equity ratio of 0.13, a current ratio of 2.79, and a quick ratio of 2.70. The fifty day moving average price for IOVA is $11.60 and a two-hundred day moving average price translates $7.58 for the stock.
The latest earnings results from Iovance Biotherapeutics Inc (NASDAQ: IOVA) was released for Dec, 2023. According to the Biotechnology Company, earnings per share came in at -$0.45, missing analysts’ expectations of -$0.43 by -0.02. This compares to -$0.64 EPS in the same period last year. For the current quarter, analysts expect IOVA to generate $2.07M in revenue.
Iovance Biotherapeutics Inc(IOVA) Company Profile
Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
